Metastatic Lung Cancer - Pipeline Review, H2 2013


#177877

54pages

Global Markets Direct

$ 2000

In Stock


Global Markets Directs, 'Metastatic Lung Cancer Pipeline Review, H2 2013', provides an overview of the indications therapeutic pipeline. This report provides information on the therapeutic development for Metastatic Lung Cancer, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Metastatic Lung Cancer. Metastatic Lung Cancer Pipeline Review, Half Year is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Directs team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • A snapshot of the global therapeutic scenario for Metastatic Lung Cancer.
  • A review of the Metastatic Lung Cancer products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • Coverage of products based on various stages of development ranging from discovery till registration stages.
  • A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
  • Coverage of the Metastatic Lung Cancer pipeline on the basis of route of administration and molecule type.
  • Key discontinued pipeline projects.
  • Latest news and deals relating to the products.

Reasons to buy

  • Identify and understand important and diverse types of therapeutics under development for Metastatic Lung Cancer.
  • Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
  • Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.
  • Devise corrective measures for pipeline projects by understanding Metastatic Lung Cancer pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.
Table of Content

Table of Contents 2
List of Tables 4
List of Figures 5

Introduction 6
Global Markets Direct Report Coverage 6
Metastatic Lung Cancer Overview 7
Therapeutics Development 8
An Overview of Pipeline Products for Metastatic Lung Cancer 8
Metastatic Lung Cancer Therapeutics under Development by Companies 10
Metastatic Lung Cancer Therapeutics under Investigation by Universities/Institutes 11
Mid Clinical Stage Products 12
Comparative Analysis 12
Early Clinical Stage Products 13
Comparative Analysis 13
Pre-Clinical Stage Products 14
Comparative Analysis 14
Metastatic Lung Cancer Therapeutics - Products under Development by Companies 15
Metastatic Lung Cancer Therapeutics - Products under Investigation by Universities/Institutes 16
Companies Involved in Metastatic Lung Cancer Therapeutics Development 17
Alkermes, Inc. 17
BioLineRx, Ltd. 18
AntiCancer, Inc. 19
Vascular Biogenics Ltd. 20
Targa Therapeutics Corp. 21
Metastatic Lung Cancer - Therapeutics Assessment 22
Assessment by Monotherapy Products 22
Assessment by Combination Products 23
Assessment by Route of Administration 24
Assessment by Molecule Type 26
Drug Profiles 28
VB-111 - Drug Profile 28
Product Description 28
Mechanism of Action 28
R&D Progress 28
GM.CD40L Cell Vaccine + [cyclophosphamide] + [tretinoin] - Drug Profile 30
Product Description 30
Mechanism of Action 30
R&D Progress 30
VEGF/rGel - Drug Profile 31
Product Description 31
Mechanism of Action 31
R&D Progress 31
CNVN-202 - Drug Profile 33
Product Description 33
Mechanism of Action 33
R&D Progress 33
BL-8040 - Drug Profile 35
Product Description 35
Mechanism of Action 35
R&D Progress 35
Sticky siRNA - Drug Profile 37
Product Description 37
Mechanism of Action 37
R&D Progress 37
Salmonella typhimurium A1-R - Drug Profile 38
Product Description 38
Mechanism of Action 38
R&D Progress 38
RDB-1419 - Drug Profile 39
Product Description 39
Mechanism of Action 39
R&D Progress 39
Beta-ManCer Vaccine - Drug Profile 40
Product Description 40
Mechanism of Action 40
R&D Progress 40
LY-364937 - Drug Profile 41
Product Description 41
Mechanism of Action 41
R&D Progress 41
Metastatic Lung Cancer Therapeutics - Drug Profile Updates 42
Metastatic Lung Cancer Therapeutics - Discontinued Products 45
Metastatic Lung Cancer Therapeutics - Dormant Products 46
Metastatic Lung Cancer - Product Development Milestones 47
Featured News & Press Releases 47
Mar 04, 2013: Starpharma's Dendrimers-based Formulation Of Doxorubicin Improves Anticancer Efficacy In Lung Metastasis Model 47
Feb 26, 2013: Pfizer's Xalkori Receives Chinese Approval For Treatment Of Non-small Cell Lung Cancer 48
Jan 18, 2013: IPAB Begins Final Hearing On Bayer's Appeal Against Natco Pharma 48
Aug 13, 2012: Health Canada Approves TARCEVA As First-Line Therapy For Treatment Of Non-Small Cell Lung Cancer 49
Jun 20, 2011: Momenta Announces Publication Of Preclinical Results Of Oncology Drug M402 In PLoS One 49
Jun 10, 2011: CureVac Presents Promising New Data For Lung Cancer Vaccine CV9201 At ASCO Conference 50
May 19, 2011: VBL Therapeutics Presents Preclinical Data For VB-111 At 14th Annual ASGCT Meeting 50
Nov 10, 2010: Silence Reports Positive Preclinical Research Findings Of Atu027 In Pulmonary Metastasis Animal Models 51

Appendix 53
Methodology 53
Coverage 53
Secondary Research 53
Primary Research 53
Expert Panel Validation 53
Contact Us 54
Disclaimer 54

Number of Products Under Development for Metastatic Lung Cancer, H2 2013 8
Products under Development for Metastatic Lung Cancer - Comparative Analysis, H2 2013 9
Number of Products under Development by Companies, H2 2013 10
Number of Products under Investigation by Universities/Institutes, H2 2013 11
Comparative Analysis by Mid Clinical Stage Development, H2 2013 12
Comparative Analysis by Early Clinical Stage Development, H2 2013 13
Comparative Analysis by Pre-Clinical Stage Development, H2 2013 14
Products under Development by Companies, H2 2013 15
Products under Investigation by Universities/Institutes, H2 2013 16
Alkermes, Inc., H2 2013 17
BioLineRx, Ltd., H2 2013 18
AntiCancer, Inc., H2 2013 19
Vascular Biogenics Ltd., H2 2013 20
Targa Therapeutics Corp., H2 2013 21
Assessment by Monotherapy Products, H2 2013 22
Assessment by Combination Products, H2 2013 23
Assessment by Stage and Route of Administration, H2 2013 25
Assessment by Stage and Molecule Type, H2 2013 27
Metastatic Lung Cancer Therapeutics - Drug Profile Updates 42
Metastatic Lung Cancer Therapeutics - Discontinued Products 45
Metastatic Lung Cancer Therapeutics - Dormant Products 46
Number of Products under Development for Metastatic Lung Cancer, H2 2013 8
Products under Development for Metastatic Lung Cancer - Comparative Analysis, H2 2013 9
Products under Development by Companies, H2 2013 10
Products under Investigation by Universities/Institutes, H2 2013 11
Mid Clinical Stage Products, H2 2013 12
Early Clinical Stage Products, H2 2013 13
Pre-Clinical Stage Products, H2 2013 14
Assessment by Monotherapy Products, H2 2013 22
Assessment by Combination Products, H2 2013 23
Assessment by Route of Administration, H2 2013 24
Assessment by Stage and Route of Administration, H2 2013 25
Assessment by Molecule Type, H2 2013 26
Assessment by Stage and Molecule Type, H2 2013 27